Kewaunee Scienti Financials
This page shows Kewaunee Scienti (KEQU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kewaunee's margin expansion rebuilt earnings, while FY2025 balance-sheet growth came more from transaction financing than routine reinvestment.
In FY2025, investing cash outflow reached$30.9M even though capex was only$2.2M , showing the year's investment spending was not mainly ordinary reinvestment. That reading is reinforced by new goodwill of$12.5M and$34.4M of long-term debt, while operating and free cash flow stayed positive, so the balance sheet expanded without the core business turning cash-hungry.
From FY2023 to FY2025, gross margin expansion from
The company still looks liquid at 2.3x current ratio, but working capital intensity increased as receivables plus inventory reached
Financial Health Signals
Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Kewaunee Scienti's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kewaunee Scienti has an operating margin of 5.9%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 38/100, indicating healthy but not exceptional operating efficiency. This is down from 7.4% the prior year.
Kewaunee Scienti's revenue surged 17.3% year-over-year to $282.0M, reflecting rapid business expansion. This strong growth earns a score of 63/100.
Kewaunee Scienti carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
Kewaunee Scienti's current ratio of 2.18 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.
Kewaunee Scienti has a free cash flow margin of 5.2%, earning a moderate score of 39/100. The company generates positive cash flow after capital investments, but with room for improvement.
Kewaunee Scienti's ROE of 12.9% shows moderate profitability relative to equity, earning a score of 52/100. This is down from 17.0% the prior year.
Kewaunee Scienti scores 3.44, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Kewaunee Scienti passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Kewaunee Scienti generates $1.94 in operating cash flow ($18.6M OCF vs $9.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Kewaunee Scienti earns $4.3 in operating income for every $1 of interest expense ($16.7M vs $3.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Kewaunee Scienti generated $282.0M in revenue in fiscal year 2026. This represents an increase of 17.3% from the prior year.
Kewaunee Scienti's EBITDA was $23.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.1% from the prior year.
Kewaunee Scienti reported $9.6M in net income in fiscal year 2026. This represents a decrease of 15.7% from the prior year.
Kewaunee Scienti earned $3.22 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 15.9% from the prior year.
Cash & Balance Sheet
Kewaunee Scienti generated $14.7M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 16.5% from the prior year.
Kewaunee Scienti held $9.9M in cash against $15.1M in long-term debt as of fiscal year 2026.
Kewaunee Scienti had 3M shares outstanding in fiscal year 2026. This represents an increase of 0.9% from the prior year.
Margins & Returns
Kewaunee Scienti's gross margin was 28.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.
Kewaunee Scienti's operating margin was 5.9% in fiscal year 2026, reflecting core business profitability. This is down 1.5 percentage points from the prior year.
Kewaunee Scienti's net profit margin was 3.4% in fiscal year 2026, showing the share of revenue converted to profit. This is down 1.3 percentage points from the prior year.
Kewaunee Scienti's ROE was 12.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 4.1 percentage points from the prior year.
Capital Allocation
Kewaunee Scienti invested $898K in research and development in fiscal year 2026. This represents a decrease of 2.3% from the prior year.
Kewaunee Scienti spent $0 on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Kewaunee Scienti invested $3.9M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 81.8% from the prior year.
KEQU Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.4M+2.9% | $69.4M-1.0% | $70.1M-1.4% | $71.1M-7.8% | $77.1M+14.9% | $67.2M+40.6% | $47.8M-1.3% | $48.4M |
| Cost of Revenue | $50.2M-1.4% | $50.9M+0.9% | $50.4M+0.4% | $50.2M-5.5% | $53.1M+8.9% | $48.8M+44.3% | $33.8M-5.8% | $35.9M |
| Gross Profit | $21.2M+14.6% | $18.5M-6.0% | $19.7M-5.8% | $20.9M-12.9% | $24.0M+30.8% | $18.4M+31.7% | $14.0M+11.7% | $12.5M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $5.2M+102.0% | $2.6M-37.1% | $4.1M-14.6% | $4.8M-43.4% | $8.5M+277.8% | $2.3M-49.3% | $4.4M+72.2% | $2.6M |
| Interest Expense | $631K-43.3% | $1.1M+4.8% | $1.1M+0.3% | $1.1M-9.0% | $1.2M+2.3% | $1.1M+157.2% | $442K-6.4% | $472K |
| Income Tax | $1.1M+101.5% | $528K-42.3% | $915K+20.2% | $761K-65.4% | $2.2M+2138.9% | -$108K-111.8% | $916K+377.1% | $192K |
| Net Income | $3.4M+389.6% | $692K-71.7% | $2.4M-21.0% | $3.1M-36.2% | $4.8M+258.2% | $1.4M-55.0% | $3.0M+37.2% | $2.2M |
| EPS (Diluted) | N/A | $0.23-72.0% | $0.82-21.2% | $1.04 | N/A | $0.45-55.4% | $1.01+36.5% | $0.74 |
KEQU Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $178.3M+1.3% | $176.0M-6.9% | $189.1M-2.3% | $193.5M-0.6% | $194.7M+2.9% | $189.1M+40.7% | $134.5M+1.9% | $132.0M |
| Current Assets | $105.4M+1.8% | $103.6M-8.9% | $113.6M-3.0% | $117.1M-1.0% | $118.4M+9.0% | $108.6M+12.6% | $96.4M+4.0% | $92.7M |
| Cash & Equivalents | $9.9M+22.0% | $8.2M-35.3% | $12.6M-35.4% | $19.5M+30.4% | $14.9M+58.0% | $9.5M-63.6% | $26.0M+7.2% | $24.2M |
| Inventory | $30.5M-7.2% | $32.9M-7.3% | $35.5M+1.6% | $34.9M+6.3% | $32.8M+4.1% | $31.6M+69.1% | $18.7M-3.2% | $19.3M |
| Accounts Receivable | $58.7M+8.5% | $54.1M-8.3% | $59.0M+3.7% | $56.9M-8.8% | $62.4M+8.6% | $57.4M+37.1% | $41.9M-3.8% | $43.5M |
| Goodwill | $12.5M0.0% | $12.5M0.0% | $12.5M0.0% | $12.5M0.0% | $12.5M-11.8% | $14.2M | N/A | N/A |
| Total Liabilities | $101.5M-1.9% | $103.4M-11.9% | $117.4M-5.8% | $124.6M-3.0% | $128.4M+1.1% | $127.0M+72.1% | $73.8M-0.9% | $74.5M |
| Current Liabilities | $48.4M-0.9% | $48.8M+6.5% | $45.8M-9.3% | $50.5M-6.0% | $53.7M+7.1% | $50.2M+37.6% | $36.5M-0.6% | $36.7M |
| Long-Term Debt | $15.1M-7.7% | $16.3M-49.4% | $32.3M-6.2% | $34.4M-0.9% | $34.7M-0.8% | $35.0M | N/A | N/A |
| Total Equity | $74.7M+5.7% | $70.7M+1.2% | $69.9M+4.1% | $67.1M+4.1% | $64.5M+6.0% | $60.8M+2.5% | $59.3M+5.9% | $56.0M |
| Retained Earnings | $68.5M+5.2% | $65.1M+1.1% | $64.5M+3.9% | $62.0M+5.2% | $58.9M+9.0% | $54.1M+2.6% | $52.7M+6.1% | $49.7M |
KEQU Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $5.5M-53.1% | $11.6M+373.1% | -$4.3M-173.6% | $5.8M-38.4% | $9.4M+515.1% | -$2.3M-126.9% | $8.4M+1162.5% | -$794K |
| Capital Expenditures | $928K+38.9% | $668K-57.5% | $1.6M+103.6% | $771K+49.4% | $516K-25.1% | $689K+0.9% | $683K+145.7% | $278K |
| Free Cash Flow | $4.5M-58.7% | $11.0M+288.2% | -$5.8M-216.2% | $5.0M-43.5% | $8.9M+400.9% | -$3.0M-138.1% | $7.8M+823.2% | -$1.1M |
| Investing Cash Flow | -$928K-38.9% | -$668K+57.5% | -$1.6M-103.6% | -$771K-49.4% | -$516K+98.2% | -$29.4M-4208.1% | -$683K-145.7% | -$278K |
| Financing Cash Flow | -$3.0M+79.0% | -$14.1M-1548.3% | -$853K+41.7% | -$1.5M+66.3% | -$4.3M-129.6% | $14.6M+553.2% | -$3.2M-1041.4% | $343K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $1.6M | N/A | N/A | N/A |
KEQU Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.8%+3.0pp | 26.7%-1.4pp | 28.1%-1.3pp | 29.4%-1.7pp | 31.2%+3.8pp | 27.4%-1.9pp | 29.2%+3.4pp | 25.8% |
| Operating Margin | 7.3%+3.6pp | 3.7%-2.1pp | 5.9%-0.9pp | 6.8%-4.3pp | 11.0%+7.7pp | 3.4%-5.9pp | 9.3%+4.0pp | 5.3% |
| Net Margin | 4.8%+3.8pp | 1.0%-2.5pp | 3.5%-0.9pp | 4.3%-1.9pp | 6.3%+4.3pp | 2.0%-4.3pp | 6.3%+1.8pp | 4.5% |
| Return on Equity | 4.5%+3.6pp | 1.0%-2.5pp | 3.5%-1.1pp | 4.6%-2.9pp | 7.5%+5.3pp | 2.2%-2.8pp | 5.1%+1.2pp | 3.9% |
| Return on Assets | 1.9%+1.5pp | 0.4%-0.9pp | 1.3%-0.3pp | 1.6%-0.9pp | 2.5%+1.8pp | 0.7%-1.5pp | 2.2%+0.6pp | 1.7% |
| Current Ratio | 2.18+0.1 | 2.12-0.4 | 2.48+0.2 | 2.32+0.1 | 2.20+0.0 | 2.16-0.5 | 2.64+0.1 | 2.53 |
| Debt-to-Equity | 0.20-0.0 | 0.23-0.2 | 0.46-0.1 | 0.51-0.0 | 0.54-0.0 | 0.57-0.7 | 1.24-0.1 | 1.33 |
| FCF Margin | 6.3%-9.5pp | 15.8%+24.1pp | -8.3%-15.4pp | 7.1%-4.5pp | 11.5%+15.9pp | -4.4%-20.6pp | 16.2%+18.4pp | -2.2% |
Similar Companies
Frequently Asked Questions
What is Kewaunee Scienti's annual revenue?
Kewaunee Scienti (KEQU) reported $282.0M in total revenue for fiscal year 2026. This represents a 17.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kewaunee Scienti's revenue growing?
Kewaunee Scienti (KEQU) revenue grew by 17.3% year-over-year, from $240.5M to $282.0M in fiscal year 2026.
Is Kewaunee Scienti profitable?
Yes, Kewaunee Scienti (KEQU) reported a net income of $9.6M in fiscal year 2026, with a net profit margin of 3.4%.
What is Kewaunee Scienti's EBITDA?
Kewaunee Scienti (KEQU) had EBITDA of $23.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Kewaunee Scienti have?
As of fiscal year 2026, Kewaunee Scienti (KEQU) had $9.9M in cash and equivalents against $15.1M in long-term debt.
What is Kewaunee Scienti's gross margin?
Kewaunee Scienti (KEQU) had a gross margin of 28.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kewaunee Scienti's operating margin?
Kewaunee Scienti (KEQU) had an operating margin of 5.9% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Kewaunee Scienti's net profit margin?
Kewaunee Scienti (KEQU) had a net profit margin of 3.4% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Kewaunee Scienti's return on equity (ROE)?
Kewaunee Scienti (KEQU) has a return on equity of 12.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Kewaunee Scienti's free cash flow?
Kewaunee Scienti (KEQU) generated $14.7M in free cash flow during fiscal year 2026. This represents a 16.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kewaunee Scienti's operating cash flow?
Kewaunee Scienti (KEQU) generated $18.6M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Kewaunee Scienti's total assets?
Kewaunee Scienti (KEQU) had $178.3M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Kewaunee Scienti's capital expenditures?
Kewaunee Scienti (KEQU) invested $3.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Kewaunee Scienti spend on research and development?
Kewaunee Scienti (KEQU) invested $898K in research and development during fiscal year 2026.
What is Kewaunee Scienti's current ratio?
Kewaunee Scienti (KEQU) had a current ratio of 2.18 as of fiscal year 2026, which is generally considered healthy.
What is Kewaunee Scienti's debt-to-equity ratio?
Kewaunee Scienti (KEQU) had a debt-to-equity ratio of 0.20 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kewaunee Scienti's return on assets (ROA)?
Kewaunee Scienti (KEQU) had a return on assets of 5.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Kewaunee Scienti's Altman Z-Score?
Kewaunee Scienti (KEQU) has an Altman Z-Score of 3.44, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kewaunee Scienti's Piotroski F-Score?
Kewaunee Scienti (KEQU) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kewaunee Scienti's earnings high quality?
Kewaunee Scienti (KEQU) has an earnings quality ratio of 1.94x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kewaunee Scienti cover its interest payments?
Kewaunee Scienti (KEQU) has an interest coverage ratio of 4.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Kewaunee Scienti?
Kewaunee Scienti (KEQU) scores 55 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.